Dark

Check out our API

ATBPF
ANTIBE THERAPEUTICS INC
stock OTC

Inactive

Apr 8, 2024

0.2156USD+13.474%(+0.0256)33,935

Pre-market

0.00USD-100.000%(-0.19)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 6, 2021

09:51AM EST ATE.TO: Development Plan in Place for Otenaproxesul in Acute Benzinga

Nov 16, 2021

07:05AM EST Antibe Therapeutics Q2 Net Loss $8.7 Mln Or $0.17/shr Vs. Net Loss $8.9 Mln Or $0.23/shr Last Year RTTNews

07:00AM EST Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results Business Wire

Nov 1, 2021

07:00AM EDT Antibe Therapeutics Outlines Plan for Otenaproxesul's Acute Pain Program Business Wire

Oct 23, 2021

12:04PM EDT ATE.TO: Pivoting to Acute Pain Relief for Benzinga

Oct 14, 2021

07:10AM EDT Antibe Therapeutics Provides Update On Otenaproxesul RTTNews

07:01AM EDT Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline Business Wire

Sep 8, 2021

07:00AM EDT Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Sep 1, 2021

07:01AM EDT ATE.TO: Awaiting Update on Otenaproxesul Following AME Study Pause Benzinga

Aug 19, 2021

05:30PM EDT Antibe Therapeutics Announces Results of 2021 Annual Meeting Business Wire

Aug 17, 2021

07:00AM EDT Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results Business Wire

Aug 9, 2021

09:51AM EDT ATE.TO: Unexpected Liver Enzyme Elevations Leads to Pause in AME Trial Benzinga

07:00AM EDT Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference Business Wire

Aug 3, 2021

07:15AM EDT Antibe Says Placed AME Study Of Otenaproxesul On Required Pause Because Pre-specified Safety Threshold Exceeded RTTNews

07:00AM EDT Antibe Therapeutics Provides Clinical Update for Otenaproxesul Business Wire

Jun 28, 2021

07:00AM EDT Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights Business Wire

Jun 7, 2021

07:00AM EDT Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences Business Wire

Apr 14, 2021

07:01AM EDT Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference Business Wire

Mar 29, 2021

07:04AM EDT Antibe Therapeutics Receives FDA Clearance Of IND Application For Otenaproxesul For Osteoarthritis Pain RTTNews

Feb 16, 2021

07:01AM EST OTC Markets Group Welcomes Antibe Therapeutics Inc. to OTCQX PR Newswire

Feb 9, 2021

07:05AM EST Antibe Announces Strategic Licensing Deal In China With Nuance Pharma; Entitled To US$100 Mln In Milestone Payments RTTNews

07:00AM EST Antibe Therapeutics Announces Strategic Licensing Deal in China With Nuance Pharma Business Wire

Dec 18, 2020

07:07AM EST Antibe Therapeutics Announces Intent To Unify Intellectual Property Ownership RTTNews

Nov 24, 2020

07:09AM EST Antibe Therapeutics Appoints Robert Hoffman And Jennifer McNealey To Its Board RTTNews

07:00AM EST Antibe Therapeutics Strengthens Governance and U.S. Capital Markets Expertise With Appointment of Two Independent Directors Business Wire

Nov 17, 2020

07:10AM EST Antibe Therapeutics To Complete Share Consolidation In Preparation For Potential NASDAQ Listing RTTNews

Aug 31, 2020

07:00AM EDT Antibe Therapeutics to Present at Upcoming Conferences Business Wire

Share